An in vivo demonstration of DHME-induced retardation of CRC tumor growth and reduction in tyrosine 705 phosphorylation of STAT3 within CRC tumors is fundamental to underpinning DHME’s potential as a therapeutic option for CRC treatment. Here, STAT3 is linked to neoplasm.